<DOC>
	<DOCNO>NCT01325688</DOCNO>
	<brief_summary>This study primarily design investigate whether treatment , daily three consecutive day , PEP005 ( ingenol mebutate ) Gel , 0.05 % safe tolerable patient superficial Basal Cell Carcinoma ( sBCC ) lesion trunk extremity .</brief_summary>
	<brief_title>PEP005 Gel - Evaluation Safety Efficacy Ingenol Mebutate Gel Superficial Basal Cell Carcinoma Trunk Extremities</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Must male female least 18 year age Female patient must : nonchildbearing potential childbearing potential negative serum urine pregnancy test use effective contraception Ability provide inform consent primary diagnose histologically confirm sBCC locate trunk extremity suitable excision location sBCC lesion within 10cm incompletely heal wound , hand foot , breast woman , anogenital area . Undergone cosmetic therapeutic procedure within 2cm selected treatment area 2 week prior screen visit . Use acidcontaining therapeutic product within 2 cm select treatment area 2 week prior screen visit Use topical moisturisers/creams/lotions ( nonmedicated/nonirritant salve acceptable ) , artificial tanner topical steroid : within 2 cm select treatment area . Have receive treatment immunomodulators , interferon/interferon inducer , systematic medication suppress immune system UVB last 4 week Have undergone treatment 5FU , imiquimod , diclofenac photodynamic therapy within 2 cm select treatment area within 8 week prior screen visit . Use systemic retinoids . Those currently participate clinical trial Those know suspect able comply requirement protocol Females pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>PEP005</keyword>
	<keyword>Peplin</keyword>
	<keyword>sBCC</keyword>
</DOC>